Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression-Reference-Cited by-同舟云学术

Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression

Published:2001-08 Issue:2 Volume:58 Page:146-150
ISSN:0090-4295
Container-title:Urology
language:en
Short-container-title:Urology

Author:

Wirth M,Tyrrell C,Wallace M,Delaere K.P,Sánchez-Chapado M,Ramon J,Hetherington J,Pina F,Heynes C.F,Borchers T.M,Morris T,Stone A

Publisher

Elsevier BV

Subject

Urology

Reference14 articles.

1. Cancer statistics, 1998;Landis;CA Cancer J Clin,1998

2. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer;Iversen;J Urol,2000

3. The bicalutamide early prostate cancer program;See;Urol Oncol,2001

4. Long term results of immediate adjuvant hormonal therapy with goserelin in patients with locally advanced prostate cancer treated with radiotherapy—a phase III EORTC study;Bolla;Eur J Cancer,1999

5. Immediate hormonal therapy in men with node-positive prostate cancer;Messing;N Engl J Med,1999

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug-induced gynecomastia: A systematic review and meta-analysis of randomized clinical trials;Archivio Italiano di Urologia e Andrologia;2021-12-21

2. Scalable and sustainable synthetic assessment between solid-state metathesis and sonochemically derived electrocatalysts (strontium molybdate) for the precise anti-androgen bicalutamide (Casodex™) detection;Microchemical Journal;2021-09

3. Early versus deferred standard androgen suppression therapy for advanced hormone-sensitive prostate cancer;Cochrane Database of Systematic Reviews;2019-06-11

4. Antiandrogen Monotherapy in the Treatment of Prostate Cancer;Prostate Cancer;2016

5. Differences in Time to Disease Progression Do Not Predict for Cancer-specific Survival in Patients Receiving Immediate or Deferred Androgen-deprivation Therapy for Prostate Cancer: Final Results of EORTC Randomized Trial 30891 with 12 Years of Follow-up;European Urology;2014-11